Huntington's disease: Pathological mechanisms and therapeutic strategies

Cell Transplantation

Volumn 16, Issue 3, 2007, Pages 301-312

  Ramaswamy, Shilpa ^a   Shannon, Kathleen M ^a   Kordower, Jeffrey H ^a,b,c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Jean Schweppe Armour Professor of Neurological Science   (United States)

^c Research Center for Brain Repair   (United States)

Author keywords

Cell death; Huntington's disease; Symptoms; Therapies

Indexed keywords

ALPHA TOCOPHEROL; AMANTADINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; CLOZAPINE; CREATINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HUNTINGTIN; MEMANTINE; OLANZAPINE; PLACEBO; REMACEMIDE; RISPERIDONE; TETRABENAZINE; UBIDECARENONE; UNSATURATED FATTY ACID; NEUROPROTECTIVE AGENT; SIGNAL PEPTIDE;

AKATHISIA; BRAIN CORTEX; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CORPUS STRIATUM; DEGENERATIVE DISEASE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DROWSINESS; DRUG MEGADOSE; DRUG RECEPTOR BINDING; EXCITOTOXICITY; FETAL TISSUE TRANSPLANTATION; GENE; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; IT15 GENE; MENTAL DISEASE; MONOTHERAPY; MOOD; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NERVE CELL NETWORK; NEUROPROTECTION; PARKINSONISM; PRIORITY JOURNAL; PROTEIN DEGRADATION; RNA INTERFERENCE; SIDE EFFECT; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; CELL DEATH; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALIA;

CELL DEATH; FETAL TISSUE TRANSPLANTATION; HUMANS; HUNTINGTON DISEASE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROPROTECTIVE AGENTS;

EID: 34250659732     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000007783464687     Document Type: Conference Paper

References (112)

1. Albin, R. L.; Young, A. B.; Penney, J. B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12: 366-375; 1989.
2. Alexander, G. E.; Crutcher, M. D. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci. 13:266-271; 1990.
3. Alston, T. A.; Mela, L.; Bright, H. J. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc. Natl. Acad. Sci. USA 74:3767-3771; 1977.
4. Andrew, S. E.; Goldberg, Y. P.; Kremer, B.; Telenius, H.; Theilmann, J.; Adam, S.; Starr, E.; Squitieri, F.; Lin, B.; Kalchman, M. A. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 4:398-403; 1993.
5. Appel, S. H. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann. Neurol. 10:499-505; 1981.
6. Araujo, D. M.; Hilt, D. C. Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease. Neuroscience 81:1099-1110; 1997.
7. Aylward, E. H.; Rosenblatt, A.; Field, K.; Yallapragada, V.; Kieburtz, K.; McDermott, M.; Raymond, L. A.; Almqvist, E. W.; Hayden, M.; Ross, C. A. Caudate volume as an outcome measure in clinical trials for Huntington's disease: A pilot study. Brain Res. Bull. 62: 137-141; 2003.
8. Bachoud-Levi, A.; Bourdet, C.; Brugieres, P.; Nguyen, J. P.; Grandmougin, T.; Haddad, B.; Jeny, R.; Bartolomeo, P.; Boisse, M. F.; Barba, G. D.; Degos, J. D.; Ergis, A. M.; Lefaucheur, J. P.; Lisovoski, F.; Pailhous, E.; Remy, P.; Palfi, S.; Defer, G. L.; Cesaro, P.; Hantraye, P.; Peschanski, M. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp. Neurol. 161:194-202; 2000.
9. Bachoud-Levi, A. C.; Deglon, N.; Nguyen, J. P.; Bloch, J.; Bourdet, C.; Winkel, L.; Remy, P.; Goddard, M.; Lefaucheur, J. P.; Brugieres, P.; Baudic, S.; Cesaro, P.; Peschanski, M.; Aebischer, P. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum. Gene Ther. 11:1723-1729; 2000.
10. Bachoud-Levi, A. C.; Gaura, V.; Brugieres, P.; Lefaucheur, J. P.; Boisse, M. F.; Maison, P.; Baudic, S.; Ribeiro, M. J.; Bourdet, C.; Remy, P.; Cesaro, P.; Hantraye, P.; Peschanski, M. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: A long-term follow-up study. Lancet Neurol. 5: 303-309; 2006.
11. Bachoud-Levi, A. C.; Remy, P.; Nguyen, J. P.; Brugieres, P.; Lefaucheur, J. P.; Bourdet, C.; Baudic, S.; Gaura, V.; Maison, P.; Haddad, B.; Boisse, M. F.; Grandmougin, T.; Jeny, R.; Bartolomeo, P.; Dalla, B. G.; Degos, J. D.; Lisovoski, F.; Ergis, A. M.; Pailhous, E.; Cesaro, P.; Hantraye, P.; Peschanski, M. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356: 1975-1979; 2000.
12. Beal, M. F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31:119-130; 1992.
13. Beal, M. F.; Brouillet, E.; Jenkins, B. G.; Ferrante, R. J.; Kowall, N. W.; Miller, J. M.; Storey, E.; Srivastava, R.; Rosen, B. R.; Hyman, B. T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13:4181-4192; 1993.
14. Beal, M. F.; Ferrante, R. J.; Swartz, K. J.; Kowall, N. W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11:1649-1659; 1991.
15. Bloch, J.; Bachoud-Levi, A. C.; Deglon, N.; Lefaucheur, J. P.; Winkel, L.; Palfi, S.; Nguyen, J. P.; Bourdet, C.; Gaura, V.; Remy, P.; Brugieres, P.; Boisse, M. F.; Baudic, S.; Cesaro, P.; Hantraye, P.; Aebischer, P.; Peschanski, M. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: Results of a phase I study. Hum. Gene Ther. 15:968-975; 2004.
16. Blum, D.; Gall, D.; Cuvelier, L.; Schiffmann, S. N. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. Neuroreport 12:1769-1772; 2001.
17. Bonelli, R. M.; Hofmann, P. A review of the treatment options for Huntington's disease. Expert Opin. Pharmacother. 5:767-776; 2004.
18. Browne, S. E.; Bowling, A. C.; MacGarvey, U.; Baik, M. J.; Berger, S. C.; Muqit, M. M.; Bird, E. D.; Beal, M. F. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia. Ann. Neurol. 41:646-653; 1997.
19. Burke, J. R.; Enghild, J. J.; Martin, M. E.; Jou, Y. S.; Myers, R. M.; Roses, A. D.; Vance, J. M.; Strittmatter, W. J. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat. Med. 2:347-350; 1996.
20. Bylsma, F. W.; Brandt, J.; Strauss, M. E. Aspects of procedural memory are differentially impaired in Huntington's disease. Arch. Clin. Neuropsychol. 5:287-297; 1990.
21. Calon, F.; Rajput, A. H.; Hornykiewicz, O.; Bedard, P. J.; Di Paolo, T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 14:404-416; 2003.
22. Canals, J. M.; Checa, N.; Marco, S.; Akerud, P.; Michels, A.; Perez-Navarro, E.; Tolosa, E.; Arenas, E.; Alberch, J. Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. J. Neurosci. 21:117-124; 2001.
23. Canals, J. M.; Pineda, J. R.; Torres-Peraza, J. F.; Bosch, M.; Martin-Ibanez, R.; Munoz, M. T.; Mengod, G.; Ernfors, P.; Alberch, J. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 24:7727-7739; 2004.
24. Chen, Z. J.; Kren, B. T.; Wong, P. Y.; Low, W. C.; Steer, C. J. Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference. Biochem. Biophys. Res. Commun. 329:646-652; 2005.
25. Coles, C. J.; Edmondson, D. E.; Singer, T. P. Inactivation of succinate dehydrogenase by 3-nitropropionate. J. Biol. Chem. 254:5161-5167; 1979.
26. Creighton, S.; Almqvist, E. W.; MacGregor, D.; Fernandez, B.; Hogg, H.; Beis, J.; Welch, J. P.; Riddell, C.; Lokkesmoe, R.; Khalifa, M.; MacKenzie, J.; Sajoo, A.; Farrell, S.; Robert, F.; Shugar, A.; Summers, A.; Meschino, W.; Allingham-Hawkins, D.; Chiu, T.; Hunter, A.; Allanson, J.; Hare, H.; Schween, J.; Collins, L.; Sanders, S.; Greenberg, C.; Cardwell, S.; Lemire, E.; MacLeod, P.; Hayden, M. R. Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: The experience in Canada from 1987 to 2000. Clin. Genet. 63:462-475; 2003.
27. Dass, B.; Kladis, T.; Chu, Y.; Kordower, J. H. RET expression does not change with age in the substantia nigra pars compacta of rhesus monkeys. Neurobiol. Aging 27: 857-861; 2006.
28. Dedeoglu, A.; Kubilus, J. K.; Yang, L.; Ferrante, K. L.; Hersch, S. M.; Beal, M. F.; Ferrante, R. J. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem. 85:1359-1367; 2003.
29. Ducray, A.; Krebs, S. H.; Schaller, B.; Seiler, R. W.; Meyer, M.; Widmer, H. R. GDNF family ligands display distinct action profiles on cultured GABAergic and serotonergic neurons of rat ventral mesencephalon. Brain Res. 1069:104-112; 2006.
30. Dunnett, S. B.; Carter, R. J.; Watts, C.; Torres, E. M.; Mahal, A.; Mangiarini, L.; Bates, G.; Morton, A. J. Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp. Neurol. 154:31-40; 1998.
31. Dunnett, S. B.; Rosser, A. E. Cell therapy in Huntington's disease. NeuroRx 1:394-405; 2004.
32. Ende, N.; Chen, R. Human umbilical cord blood cells ameliorate Huntington's disease in transgenic mice. J. Med. 32:231-240; 2001.
33. Ferrante, R. J.; Kowall, N. W.; Cipolloni, P. B.; Storey, E.; Beal, M. F. Excitotoxin lesions in primates as a model for Huntington's disease: Histopathologic and neurochemical characterization. Exp. Neurol. 119:46-71; 1993.
34. Freeman, T. B.; Cicchetti, F.; Hauser, R. A.; Deacon, T. W.; Li, X. J.; Hersch, S. M.; Nauert, G. M.; Sanberg, P. R.; Kordower, J. H.; Saporta, S.; Isacson, O. Transplanted fetal striatum in Huntington's disease: Phenotypic development and lack of pathology. Proc. Natl. Acad. Sci. USA 97:13877-13882; 2000.
35. Gardian, G.; Vecsei, L. Huntington's disease: Pathomechanism and therapeutic perspectives. J. Neural Transm. 111:1485-1494; 2004.
36. Gaura, V.; Bachoud-Levi, A. C.; Ribeiro, M. J.; Nguyen, J. P.; Frouin, V.; Baudic, S.; Brugieres, P.; Mangin, J. F.; Boisse, M. F.; Palfi, S.; Cesaro, P.; Samson, Y.; Hantraye, P.; Peschanski, M.; Remy, P. Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain 127:65-72; 2004.
37. Gauthier, L. R.; Charrin, B. C.; Borrell-Pages, M.; Dompierre, J. P.; Rangone, H.; Cordelieres, F. P.; De Mey, J.; MacDonald, M. E.; Lessmann, V.; Humbert, S.; Saudou, F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127-138; 2004.
38. Gratacos, E.; Perez-Navarro, E.; Tolosa, E.; Arenas, E.; Alberch, J. Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members. J. Neurochem. 78:1287-1296; 2001.
39. Gu, M.; Gash, M. T.; Mann, V. M.; Javoy-Agid, F.; Cooper, J. M.; Schapira, A. H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39: 385-389; 1996.
40. Guyot, M. C.; Hantraye, P.; Dolan, R.; Palfi, S.; Maziere, M.; Brouillet, E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 79:45-56; 1997.
41. Hahn-Barma, V.; Deweer, B.; Durr, A.; Dode, C.; Feingold, J.; Pillon, B.; Agid, Y.; Brice, A.; Dubois, B. Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. J. Neurol. Neurosurg. Psychiatry 64:172-177; 1998.
42. Harper, P. S.; Morris, M. J.; Tyler, A. Genetic testing for Huntington's disease. BMJ 300:1089-1090; 1990.
43. Harper, S. Q.; Staber, P. D.; He, X.; Eliason, S. L.; Martins, I. H.; Mao, Q.; Yang, L.; Kotin, R. M.; Paulson, H. L.; Davidson, B. L. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 102: 5820-5825; 2005.
44. Harris, R. C.; Soderlund, K.; Hultman, E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin. Sci. (Lond.) 83: 367-374; 1992.
45. Hauser, R. A.; Sandberg, P. R.; Freeman, T. B.; Stoessl, A. J. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 58:1704; 2002.
46. Heindel, W. C.; Butters, N.; Salmon, D. P. Impaired learning of a motor skill in patients with Huntington's disease. Behav. Neurosci. 102:141-147; 1988.
47. Hersch, S. M.; Gevorkian, S.; Marder, K.; Moskowitz, C.; Feigin, A.; Cox, M.; Como, P.; Zimmerman, C.; Lin, M.; Zhang, L.; Ulug, A. M.; Beal, M. F.; Matson, W.; Bogdanov, M.; Ebbel, E.; Zaleta, A.; Kaneko, Y.; Jenkins, B.; Hevelone, N.; Zhang, H.; Yu, H.; Schoenfeld, D.; Ferrante, R.; Rosas, H. D. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66:250-252; 2006.
48. Hickey, M. A.; Chesselet, M. F. The use of transgenic and knock-in mice to study Huntington's disease. Cytogenet. Genome Res. 100:276-286; 2003.
49. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983; 1993.
50. Huntington Study Group. http://www.huntington-studygroup.org; 2006.
51. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57:397-404; 2001.
52. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology 66:366-372; 2006.
53. Huntington, G. On chorea. J. Neuropsychiatry Clin. Neurosci. 15:109-112; 2003.
54. Isacson, O.; Brundin, P.; Gage, F. H.; Björklund, A. Neural grafting in a rat model of Huntington's disease: Progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting. Neuroscience 16:799-817; 1985.
55. Isacson, O.; Dunnett, S. B.; Björklund, A. Graft-induced behavioral recovery in an animal model of Huntington disease. Proc. Natl. Acad. Sci. USA 83:2728-2732; 1986.
56. Kasparova, S.; Sumbalova, Z.; Bystricky, P.; Kucharska, J.; Liptaj, T.; Mlynarik, V.; Gvozdjakova, A. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem. Int. 48:93-99; 2006.
57. Kidd, P. M. Neurodegeneration from mitochondrial insufficiency: Nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. Altera. Med. Rev. 10:268-293; 2005.
58. Koller, W. C.; Davenport, J. Genetic testing in Huntington's disease. Ann. Neurol. 16:511-513; 1984.
59. Kopyov, O. V.; Jacques, S.; Lieberman, A.; Duma, C. M.; Eagle, K. S. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp. Neurol. 149:97-108; 1998.
60. Lange, K. W.; Sahakian, B. J.; Quinn, N. P.; Marsden, C. D.; Robbins, T. W. Comparison of executive and visuospatial memory function in Huntington's disease and dementia of Alzheimer type matched for degree of dementia. J. Neurol. Neurosurg. Psychiatry 58:598-606; 1995.
61. Lee, S. T.; Chu, K.; Park, J. E.; Lee, K.; Kang, L.; Kim, S. U.; Kim, M. Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model. Neurosci. Res. 52:243-249; 2005.
62. Lescaudron, L.; Unni, D.; Dunbar, G. L. Autologous adult bone marrow stem cell transplantation in an animal model of huntington's disease: Behavioral and morphological outcomes. Int. J. Neurosci. 113:945-956; 2003.
63. Lucetti, C.; Del Dotto, P.; Gambaccini, G.; Dell'Agnello, G.; Bernardini, S.; Rossi, G.; Murri, L.; Bonuccelli, U. IV amantadine improves chorea in Huntington's disease: An acute randomized, controlled study. Neurology 60: 1995-1997; 2003.
64. Ludolph, A. C.; He, F.; Spencer, P. S.; Hammerstad, J.; Sabri, M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18:492-498; 1991.
65. Machida, Y.; Okada, T.; Kurosawa, M.; Oyama, F.; Ozawa, K.; Nukina, N. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem. Biophys. Res. Commun. 343:190-197; 2006.
66. McBride, J. L.; Behrstock, S. P.; Chen, E. Y.; Jakel, R. J.; Siegel, I.; Svendsen, C. N.; Kordower, J. H. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J. Comp Neurol. 475:211-219; 2004.
67. McBride, J. L.; During, M. J.; Wuu, J.; Chen, E. Y.; Leurgans, S. E.; Kordower, J. H. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp. Neurol. 181: 213-223; 2003.
68. Menalled, L. B. Knock-in mouse models of Huntington's disease. NeuroRx 2:465-470; 2005.
69. Meriin, A. B.; Mabuchi, K.; Gabai, V. L.; Yaglom, J. A.; Kazantsev, A.; Sherman, M. Y. Intracellular aggregation of polypeptides with expanded polyglutamine domain is stimulated by stress-activated kinase MEKK1. J. Cell Biol. 153:851-864; 2001.
70. Naimi, S.; Jeny, R.; Hantraye, P.; Peschanski, M.; Riche, D. Ontogeny of human striatal DARPP-32 neurons in fetuses and following xenografting to the adult rat brain. Exp. Neurol. 137:15-25; 1996.
71. Nucifora, Jr., F. C.; Sasaki, M.; Peters, M. F.; Huang, H.; Cooper, J. K.; Yamada, M.; Takahashi, H.; Tsuji, S.; Troncoso, J.; Dawson, V. L.; Dawson, T. M.; Ross, C. A. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291:2423-2428; 2001.
72. Nutt, J. G.; Burchiel, K. J.; Cornelia, C. L.; Jankovic, J.; Lang, A. E.; Laws, Jr., E. R.; Lozano, A. M.; Penn, R. D.; Simpson, Jr., R. K.; Stacy, M.; Wooten, G. F. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60:69-73; 2003.
73. Omi, K.; Hachiya, N. S.; Tokunaga, K.; Kaneko, K. siRNA-mediated inhibition of endogenous Huntington disease gene expression induces an aberrant configuration of the ER network in vitro. Biochem. Biophys. Res. Commun. 338:1229-1235; 2005.
74. Ondo, W. G.; Mejia, N. I.; Hunter, C. B. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat. Disord.; 2006.
75. Ondo, W. G.; Tintner, R.; Thomas, M.; Jankovic, J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin. Neuropharmacol. 25:300-302; 2002.
76. O'Suilleabhain, P.; Dewey, Jr., R. B. A randomized trial of amantadine in Huntington disease. Arch. Neurol. 60: 996-998; 2003.
77. Palfi, S.; Leventhal, L.; Goetz, C. G.; Hantraye, T.; Roitberg, B. Z.; Sramek, J.; Emborg, M.; Kordower, J. H. Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys. Mov. Disord. 15:524-530; 2000.
78. Papa, S. M.; Chase, T. N. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol. 39:574-578; 1996.
79. Perez, M. K.; Paulson, H. L.; Pendse, S. J.; Saionz, S. J.; Bonini, N. M.; Pittman, R. N. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J. Cell Biol. 143:1457-1470; 1998.
80. Perez-Navarro, E.; Akerud, P.; Marco, S.; Canals, J. M.; Tolosa, E.; Arenas, E.; Alberch, J. Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease. Neuroscience 98:89-96; 2000.
81. Perez-Navarro, E.; Arenas, E.; Marco, S.; Alberch, J. Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo. Eur. J. Neurosci. 11:241-249; 1999.
82. Perez-Navarro, E.; Canudas, A. M.; Akerund, P.; Alberch, J.; Arenas, E. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J. Neurochem. 75:2190-2199; 2000.
83. Philpott, L. M.; Kopyov, O. V.; Lee, A. J.; Jacques, S.; Duma, C. M.; Caine, S.; Yang, M.; Eagle, K. S. Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: Three case presentations. Cell Transplant. 6:203-212; 1997.
84. Pineda, J. R.; Rubio, N.; Akerud, P.; Urban, N.; Badimon, L.; Arenas, E.; Alberch, J.; Blanco, J.; Canals, J. M. Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: Optical neuroimage tracking of brain-grafted cells. Gene Ther.; 2006.
85. Ramaswamy, S.; McBride, J. L.; Zhou, L.; Berry-Kravis, E. M.; Brandon, E. P.; Herzog, C. D.; Gasmi, M.; Bartus, R. T.; Kordower, J. H. AAV-Neurturin (Cere-120) therapy in a transgenic mouse model of Huntington's disease. Soc. Neurosci. Abstr. 472.11; 2006.
86. Ramos-Arroyo, M. A.; Moreno, S.; Valiente, A. Incidence and mutation rates of Huntington's disease in Spain: Experience of 9 years of direct genetic testing. J. Neurol. Neurosurg. Psychiatry 76:337-342; 2005.
87. Regulier, E.; Pereira, d. A.; Sommer, B.; Aebischer, P.; Deglon, N. Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. Hum. Gene Ther. 13:1981-1990; 2002.
88. Reiner, A.; Albin, R. L.; Anderson, K. D.; D'Amato, C. J.; Penney, J. B.; Young, A. B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. USA 85:5733-5737; 1988.
89. Roberts, R. C.; Ahn, A.; Swartz, K. J.; Beal, M. F.; DiFiglia, M. Intrastriatal injections of quinolinic acid or kainic acid: Differential patterns of cell survival and the effects of data analysis on outcome. Exp. Neurol. 124: 274-282; 1993.
90. Rosser, A. E.; Barker, R. A.; Harrower, T.; Watts, C.; Farrington, M.; Ho, A. K.; Burnstein, R. M.; Menon, D. K.; Gillard, J. H.; Pickard, J.; Dunnett, S. B. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J. Neurol. Neurosurg. Psychiatry 73:678-685; 2002.
91. Sanchez, I.; Xu, C. J.; Juo, P.; Kakizaka, A.; Blenis, J.; Yuan, J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22:623-633; 1999.
92. Sathasivam, K.; Hobbs, C.; Mangiarini, L.; Mahal, A.; Turmaine, M.; Doherty, P.; Davies, S. W.; Bates, G. P. Transgenic models of Huntington's disease. Philos. Trans. R. Soc. Lond B Biol. Sci. 354:963-969; 1999.
93. Saudou, F.; Finkbeiner, S.; Devys, D.; Greenberg, M. E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66; 1998.
94. Schilling, G.; Coonfield, M. L.; Ross, C. A.; Borchelt, D. R. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 315:149-153; 2001.
95. Shear, D. A.; Haik, K. L.; Dunbar, G. L. Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport 11:1833-1837; 2000.
96. Silber, E.; Kromberg, J.; Temlett, J. A.; Krause, A.; Saffer, D. Huntington's disease confirmed by genetic testing in five African families. Mov Disord. 13:726-730; 1998.
97. Smith, K. M.; Matson, S.; Matson, W. R.; Cormier, K.; Del Signore, S. J.; Hagerty, S. W.; Stack, E. C.; Ryu, H.; Ferrante, R. J. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762:616-626; 2006.
98. Stack, E. C.; Smith, K. M.; Ryu, H.; Cormier, K.; Chen, M.; Hagerty, S. W.; Del Signore, S. J.; Cudkowicz, M. E.; Friedlander, R. M.; Ferrante, R. J. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim. Biophys. Acta 1762:373-380; 2006.
99. Tabrizi, S. J.; Blamire, A. M.; Manners, D. N.; Rajagopalan, B.; Styles, P.; Schapira, A. H.; Warner, T. T. Creatine therapy for Huntington's disease: Clinical and MRS findings in a 1-year pilot study. Neurology 61:141-142; 2003.
100. Tabrizi, S. J.; Blamire, A. M.; Manners, D. N.; Rajagopalan, B.; Styles, P.; Schapira, A. H.; Warner, T. T. High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study. Neurology 64:1655-1656; 2005.
101. Tabrizi, S. J.; Cleeter, M. W.; Xuereb, J.; Taanman, J. W.; Cooper, J. M.; Schapira, A. H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 45:25-32; 1999.
102. Vaddadi, K. S.; Courtney, P.; Gilleard, C. J.; Manku, M. S.; Horrobin, D. F. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res. 27:313-323; 1989.
103. Vaddadi, K. S.; Gilleard, C. J.; Soosai, E.; Polonowita, A. K.; Gibson, R. A.; Burrows, G. D. Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophr. Res. 20:287-294; 1996.
104. Vaddadi, K. S.; Soosai, E.; Chiu, E.; Dingjan, P. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport 13:29-33; 2002.
105. van Vugt, J. P.; Siesling, S.; Vergeer, M.; van der Velde, E. A.; Roos, R. A. Clozapine versus placebo in Huntington's disease: A double blind randomised comparative study. J. Neurol. Neurosurg. Psychiatry 63:35-39; 1997.
106. Verbessem, P.; Lemiere, J.; Eijnde, B. O.; Swinnen, S.; Vanhees, L.; Van Leemputte, M.; Hespel, P.; Dom, R. Creatine supplementation in Huntington's disease: A placebo-controlled pilot trial. Neurology 61:925-930; 2003.
107. Verhagen, M. L.; Morris, M. J.; Farmer, C.; Gillespie, M.; Mosby, K.; Wuu, J.; Chase, T. N. Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 59:694-699; 2002.
108. von Horsten, S.; Schmitt, I.; Nguyen, H. P.; Holzmann, C.; Schmidt, T.; Walther, T.; Bader, M.; Pabst, R.; Kobbe, P.; Krotova, J.; Stiller, D.; Kask, A.; Vaarmann, A.; Rathke-Hartlieb, S.; Schulz, J. B.; Grasshoff, U.; Bauer, I.; Vieira-Saecker, A. M.; Paul, M.; Jones, L.; Lindenberg, K. S.; Landwehrmeyer, B.; Bauer, A.; Li, X. J.; Riess, O. Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 12:617-624; 2003.
109. Waelter, S.; Boeddrich, A.; Lurz, R.; Scherzinger, E.; Lueder, G.; Lehrach, H.; Wanker, E. E. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell 12:1393-1407; 2001.
110. Wang, Y. L.; Liu, W.; Wada, E.; Murata, M.; Wada, K.; Kanazawa, I. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci. Res. 53:241-249; 2005.
111. Zala, D.; Bensadoun, J. C.; Pereira, d. A.; Leavitt, B. R.; Gutekunst, C. A.; Aebischer, P.; Hayden, M. R.; Deglon, N. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Exp. Neurol. 185:26-35; 2004.
112. Zuccato, C.; Ciammola, A.; Rigamonti, D.; Leavitt, B. R.; Goffredo, D.; Conti, L.; MacDonald, M. E.; Friedlander, R. M.; Silani, V.; Hayden, M. R.; Timmusk, T.; Sipione, S.; Cattaneo, E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293:493-498; 2001.